US Pharma MarketingEnterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled
A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis (CF) drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special…
A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously.
Source: FierceBiotech